Migraine Study Participation Encouraged During Migraine Awareness Month
Madison, Wis -- (June 8, 2012) June is Migraine Awareness Month and Quincy Bioscience is partnering with MAGNUM, America’s preeminent migraine advocacy and support group to stress the importance of clinical trial participation.
The theme for this year’s Migraine Awareness Month is “Help Make Migraines Visible.” In keeping with the theme, Quincy Bioscience is using social media to encourage migraineurs to apply for an innovative research study to evaluate the effectiveness of the jellyfish protein apoaequorin on quality of life for migraine sufferers. Migraine bloggers are welcome to post study information found at www.onlinemigrainetrial.org.
“Trial participation is highly important for the 36 million American migraineurs”, says Michael John Coleman, Executive Director of MAGNUM. “It is through research that we learn more about this debilitating disease and what can be done to cure it.”
The Online Migraine Trial is a patient-rated outcomes study in which participants complete validated rating scales via the internet over a three month period of time. Migraineurs 18 to 65 years old who experience 3 or more migraines per month are encouraged to apply at www.onlinemigrainetrial.com.
Apoaequorin is a naturally-sourced calcium-binding protein which has proven neuroprotective by its ability to help to regulate intracellular calcium levels. High levels of intracellular calcium are believed to be one cause of the cortical spreading depression associated with migraine headaches.
Migraines are a chronic neurological disease and affect over 30 million adult Americans, with women three times more likely to suffer from recurring migraines.
The study offers migraine sufferers the opportunity to enroll and participate from their own homes. Unlike conventional trials which may require blood draws and clinic visits, the Online Migraine Trial is non-invasive and is convenient to participate.
About Quincy Bioscience
Quincy Bioscience is a biotechnology company based in Madison, Wisconsin focused on the discovery and development of novel compounds to improve cognitive performance and therapeutics to treat age related memory loss and diseases of aging. The company’s technology focuses on restoring calcium balance related to neurodegenerative disorders and other destructive age-related mechanisms.
MAGNUM is a non-profit public awareness group focusing on Migraine issues. MAGNUM stands for Migraine Awareness Group: a National Understanding for Migraineurs. Unlike other national non-profits, such as the National Headache Foundation, AHS, and ACHE, MAGNUM is dedicated to Migraine disease alone, vs. headache and Migraine disease, and therefore acts as a dedicated spokesman for Migraine. MAGNUM was formed in late 1993 to educate the public and the government about the serious nature of Migraine disease and to address much of the misinformation about Migraine in the media and in certain outdated medical literature.